Difference between revisions of "Ranimustine (Cymerin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Adult T-cell leukemia-lymphoma medications" to "Category:Adult T-cell leukemia/lymphoma medications") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Adult T-cell leukemia/lymphoma" to "[[Category:Adult T-cell leukemia-lymphoma") |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 13: | Line 13: | ||
[[Category:Nitrosoureas]] | [[Category:Nitrosoureas]] | ||
| − | [[Category:Adult T-cell leukemia | + | [[Category:Adult T-cell leukemia-lymphoma medications]] |
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Latest revision as of 16:23, 23 November 2019
Mechanism of action
From the NCI Drug Dictionary: A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells.
Diseases for which it used
Also known as
- Generic name: MCNU, ranomustine
- Brand names: Cymer, Cymerin